Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine

Infection. 2003 Dec;31(6):392-7. doi: 10.1007/s15010-003-3121-6.

Abstract

Background: The aim of this study was to investigate the clinical and epidemiological characteristics of meningococcal disease in Catalonia (Spain) after vaccination with the polysaccharide vaccine.

Patients and methods: Cases were collected by the Statutory Diseases Reporting System.

Results: 176 cases were reported, an overall incidence of 2.9/100,000 persons/year. 60% of cases occurred during winter and spring. The case fatality rate was 6.3%. The highest age incidence was in children under 2 years of age (48/100,000 persons/year). Comparison of the cases detected by the Statutory Diseases Reporting System with those obtained by the Microbiological Reporting System shows that meningococcal disease surveillance in Catalonia was relatively complete (95.7%), with a positive predictive value of 66.3%. 115 cases (65%) were culture-confirmed with a rate of 1.9/100,000 persons/year. 86 (75%) cases were due to Neisseria meningitidis serogroup B and 21 to serogroup C (18%).

Conclusion: Although infections due to serogroup C have decreased after mass vaccination with the polysaccharide vaccine, it is likely that the number of infections will decrease further with the conjugate meningococcal group C vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Age Distribution
  • Child
  • Child, Preschool
  • Female
  • Follow-Up Studies
  • Humans
  • Immunization Programs
  • Infant
  • Male
  • Mass Vaccination*
  • Meningitis, Meningococcal / diagnosis
  • Meningitis, Meningococcal / epidemiology
  • Meningitis, Meningococcal / prevention & control
  • Meningococcal Infections / diagnosis
  • Meningococcal Infections / epidemiology*
  • Meningococcal Infections / prevention & control*
  • Meningococcal Vaccines / administration & dosage
  • Middle Aged
  • Polysaccharides, Bacterial / administration & dosage*
  • Prevalence
  • Registries
  • Risk Assessment
  • Serologic Tests
  • Sex Distribution
  • Spain / epidemiology
  • Survival Rate
  • Time Factors

Substances

  • Meningococcal Vaccines
  • Polysaccharides, Bacterial
  • meningococcal group C polysaccharide